Sanofi posted higher-than-expected quarterly profit, aided by sales of its blockbuster skin and asthma drug Dupixent, and forecast another year of revenue and earnings growth.
www.bloomberg.com
#Sanofi #Profit #Tops #Forecasts #Plans #Billion #Share #Buyback
Sanofi Profit Tops Forecasts, Plans €1 Billion Share Buyback
